

Late Breakers at AAD 2026

Source: Christopher G. Bunick, *Dermatology Times*, May 2026

Disease	Drug	Mechanism of action	Results
Atopic eczema	Rademikibart	IL-4R α inhibitor	47.7% achieved IGA 0/1 at week 16, 74.2% achieved EASI75 at week 16 (96.6% maintaining through week 52), itch \geq 3 54.7%
	MG-K10	IL-4R α inhibitor	59.8% achieved EASI75 at week 16
	Amlitelimab	Anti-OX40L	39.1% achieved EASI75
	Zumilokibart	IL-3 -targeted monoclonal antibody	85% of EASI75 responders maintained with 12 weekly dosing, 75% maintained with 24 weekly dosing
	KT-621	Oral STAT6 degrader	40% reduction in peak pruritus at week 4
Paediatric atopic eczema	Nemolizumab	IL-31R inhibitor	Children aged 2-11: 64-73% EASI75 at week 16
	Topical roflumilast 0.05% cream	PDE4 inhibitor	Infants 3-24 months: itch relief within 10 minutes, 58.3% achieved EASI75 at week 4
Chronic hand eczema	Delgocitinib	Pan-JAK inhibitor	Approval
	Abrocitinib	JAK1 selective inhibitor	18% reduction in modified Total Lesion Symptom Score at week 16
Alopecia areata	Rezpegaldesleukin	IL-2R agonist	16% achieved SALT20 at week 36
Psoriasis	Icotrokinra (oral)	Cyclic peptide targeting IL-23 receptor	65% achieved IGA 0/1 response at week 16
	Zasocitinib	TYK2 inhibitor	50% achieved PASI90 at week 16

	Envudeucitinib	TYK2 inhibitor	65% achieved PASI90 at week 24
	Ixekizumab + tirzepatide		40.6% PASI 100 (vs 29% for ixekizumab alone)
Vitiligo	Upadacitinib	JAK1 inhibitor	25% achieved 75% facial improvement
Hidradenitis suppurativa	Povorcitinib	Oral JAK1	71.4% achieved HiSCR50 at week 54, 20% complete resolution of inflammatory lesions
	Sonelokimab	IL-17A/F nanobody	62% achieved HiDCR75 by week 40
Dermatomyositis	Brepocitinib	JAK1/TYK2 inhibitor	62% able to taper to <2.5 mg prednisolone daily

Tabulated by drzhenli.com

@drzhenli.skin